CyberArk Software (CYBR) PT Raised to $57 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
CyberArk Software (CYBR) PT Raised to $63 at Imperial Capital
February 10, 2017 10:48 AM ESTImperial Capital raised its price target on CyberArk Software (NASDAQ: CYBR) to $63.00 (from $55.00) while maintaining a Outperform rating. CYBR reported 4Q16 revenue of $64.4mn and adjusted EPS of $0.41, above Street revenue estimates of 63.0mn and adjusted EPS estimates of $0.33.
Analyst Michael Kim... More
After-Hours Stock Movers 02/09: (INFN) (ATVI) (SWIR) Higher; (RSYS) (TCON) (YELP) Lower (more...)
February 9, 2017 6:31 PM ESTToday's After-Hours Movers
Radisys Corp (NASDAQ: RSYS) 15% LOWER; reported Q4 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $40.6 million versus the consensus estimate of $42.06 million.
TRACON Pharmaceuticals (NASDAQ: TCON) 12.4% LOWER; reported top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma (GBM) funded and conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). In the trial, TRC105 combined with Avastin® (bevacizumab) was... More
CyberArk Software (CYBR) Tops Q4 EPS by 8c
February 9, 2017 4:12 PM ESTCyberArk Software (NASDAQ: CYBR) reported Q4 EPS of $0.41, $0.08 better than the analyst estimate of $0.33. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $63.01 million.
GUIDANCE:
CyberArk Software sees Q1 2017 EPS of $0.21-$0.23, versus the consensus of... More
